Lipfendra

Merck's FDA approval of Lipfendra, the first oral PCSK9 inhibitor for hypercholesterolemia, marks a significant shift in cardiovascular treatment. With a projected peak annual sales potential of $5 billion, this approval presents substantial commercial and supply chain opportunities for Merck, demanding robust manufacturing and strategic market access planning to capitalize on its novel oral formulation.

Merck & Co.'s Lipfendra (enlicitide), the first oral PCSK9 inhibitor, received FDA approval on July 16, 2026, for high cholesterol. This approval, potentially expedited by a controversial voucher program, introduces a competitively priced alternative to injectables, crucial for Merck's post-Keytruda growth strategy. Procurement and market access teams must assess its impact on formulary strategies and patient adherence.